- Home
- JAZZ vs PNR Comparison
JAZZ vs PNR Comparison
Compare JAZZ & PNR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | JAZZ | PNR |
|---|---|---|
| Founded | 2003 | 1966 |
| Country | Ireland | United Kingdom |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Industrial Machinery/Components |
| Sector | Health Care | Industrials |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 15.0B | 13.0B |
| IPO Year | 2007 | 2003 |
Fundamental Metrics
Financial Performance| Metric | JAZZ | PNR |
|---|---|---|
| Price | $236.27 | $72.57 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 14 | 16 |
| Target Price | ★ $217.57 | $109.73 |
| AVG Volume (30 Days) | 810.7K | ★ 2.0M |
| Earning Date | 05-05-2026 | 04-28-2026 |
| Dividend Yield | N/A | ★ 1.34% |
| EPS Growth | N/A | ★ 5.88 |
| EPS | ★ 4.43 | 1.05 |
| Revenue | ★ $1,618,693,000.00 | N/A |
| Revenue This Year | $6.22 | $4.24 |
| Revenue Next Year | $7.68 | $4.82 |
| P/E Ratio | ★ $53.20 | $69.11 |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $105.00 | $69.93 |
| 52 Week High | $243.32 | $113.95 |
Technical Indicators
Market Signals| Indicator | JAZZ | PNR |
|---|---|---|
| Relative Strength Index (RSI) | 58.56 | 41.94 |
| Support Level | $224.23 | $69.93 |
| Resistance Level | $243.32 | $75.66 |
| Average True Range (ATR) | 6.98 | 1.67 |
| MACD | -1.65 | 0.57 |
| Stochastic Oscillator | 60.69 | 44.33 |
Price Performance
Historical ComparisonAbout JAZZ Jazz Pharmaceuticals plc (Ireland)
Jazz Pharmaceuticals is an Ireland-domiciled biopharmaceutical firm focused primarily on treatments for sleeping disorders and oncology. Jazz has nine approved drugs across neuroscience and oncology indications; its portfolio includes Xyrem and Xywav for narcolepsy, Zepzelca for the treatment of metastatic small cell lung cancer, Rylaze for acute lymphoblastic leukemia, and Vyxeos for acute myeloid leukemia. In May 2021, Jazz acquired GW Pharmaceuticals and gained its leading product, Epidiolex for the treatment of severe, rare forms of epilepsy.
About PNR Pentair plc.
Pentair is a global leader in the water treatment industry, with 10,000 employees and a presence in 25 countries. Its business is organized into three segments: pool, water technologies, and flow. The company offers a wide range of water solutions, including energy-efficient swimming pool equipment, filtration solutions, and commercial and industrial pumps. Pentair generated approximately $4.2 billion in revenue in 2025.